Lp(a) Falls Sharply in Trial, but Heart Events Did Not
A late-stage trial of pelacarsen lowered lipoprotein(a) by a large amount, but it did not reduce major cardiovascular events. Here’s what that means for heart-risk research.
Tag: cardiovascular disease